A New Cancer Drug Worked In Over 25% Of Patients. What Does That Mean?

A new cancer drug, during a phase I trial, placed a patient with myelodysplastic syndrome in a complete remission that has lasted for more than three years. And it did so, in a non-invasive manner, setting forth a new way of treating cancer. CPI-613, a drug made by Cornerstone Pharmaceuticals, benefited 29 percent of cancer patients during a phase I trial at Wake Forest Baptist Medical Center, enabling complete cancer removal in one patient, partial cancer removal in three and stabilization in two.

Hey, check out all the research scientist jobs. Post your resume today!